CXCR4 and neoplasm: Most recently, innovative radiopharmaceuticals such as C-X-C chemokine receptor type 4–targeted small molecules and anti-CD38 radiolabeled antibodies have shown promising results for tumor phenotype imaging and as potential theranostics.